Adjuvant Systemic Therapies for Patients with Renal Cell Carcinoma: Choosing Treatment Based on Patient-level Characteristics

Pavlos Msaouel; Petros Grivas; Tian Zhang

doi:10.1016/j.euo.2021.09.003

Adjuvant Systemic Therapies for Patients with Renal Cell Carcinoma: Choosing Treatment Based on Patient-level Characteristics

Eur Urol Oncol. 2022 Jun;5(3):265-267. doi: 10.1016/j.euo.2021.09.003. Epub 2021 Sep 21.

Authors

Pavlos Msaouel¹, Petros Grivas², Tian Zhang³

Affiliations

¹ Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: pmsaouel@mdanderson.org.
² Division of Medical Oncology, Department of Medicine, University of Washington School of Medicine, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle, WA, USA.
³ Division of Hematology and Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Simmons Comprehensive Cancer Center, Dallas, TX, USA; Division of Medical Oncology, Duke Department of Medicine, Durham, NC, USA; Duke Cancer Institute Center for Prostate & Urologic Cancers, Durham, NC, USA.

PMID: 34561204
DOI: 10.1016/j.euo.2021.09.003

Abstract

Motivated by recent presentation of the KEYNOTE-564 interim results for adjuvant pembrolizumab in clear-cell renal cell carcinoma, we discuss concepts that can guide patient-specific decision-making in selecting individuals for whom adjuvant therapies should be offered.

Publication types

Editorial

MeSH terms

Carcinoma, Renal Cell* / drug therapy
Carcinoma, Renal Cell* / pathology
Chemotherapy, Adjuvant
Combined Modality Therapy
Humans
Immunotherapy
Kidney Neoplasms* / drug therapy
Kidney Neoplasms* / pathology